Research over the past three decades has revealed the existence of a continuously operating oxygen sensing system that is present in all metazoan cell types and depends on the transcription control complex, hypoxia inducible factor (HIF) 1 . This system controls many processes that regulate adaptive changes, and contri butes to mechanisms that balance oxygen supply and demand. One direct target of HIF is erythropoietin, the transcription of which underpins the homeostatic control of red blood cell production. The identifi cation of prolyl hydroxylase domain (PHD) enzymes (also known as EGLN enzymes) as molecular oxygen sensors that control HIF has presented the opportu nity to develop smallmolecule PHD enzyme inhibitors that efficiently activate HIF in the presence of oxy gen 2,3 . These small molecules could be therapeutically useful for a range of indications, most obviously for the treatment of anaemia that results from impaired erythropoietin production.
Research over the past three decades has revealed the existence of a continuously operating oxygen sensing system that is present in all metazoan cell types and depends on the transcription control complex, hypoxia inducible factor (HIF) 1 . This system controls many processes that regulate adaptive changes, and contri butes to mechanisms that balance oxygen supply and demand. One direct target of HIF is erythropoietin, the transcription of which underpins the homeostatic control of red blood cell production. The identifi cation of prolyl hydroxylase domain (PHD) enzymes (also known as EGLN enzymes) as molecular oxygen sensors that control HIF has presented the opportu nity to develop smallmolecule PHD enzyme inhibitors that efficiently activate HIF in the presence of oxy gen 2, 3 . These small molecules could be therapeutically useful for a range of indications, most obviously for the treatment of anaemia that results from impaired erythropoietin production.
Several pharmaceutical companies have developed PHD enzyme inhibitors, some of which are currently being tested in humans. In this Review, we summarize current understanding of the therapeutic use of PHD enzyme inhibitors. In particular, we consider the ration ale for targeting PHD enzymes to increase erythropoi etin production, other potential ontarget consequences of HIF activation, possible offtarget effects on enzymes that are structurally similar to PHD enzymes, and indi cations for the use of PHD enzyme inhibitors beyond renal anaemia.
Erythropoietin in red cell production Over 98% of oxygen in the circulatory system is bound to haemoglobin in red blood cells. Consequently, the oxygen carrying capacity of the blood is determined by the concentration of haemoglobin, which is closely related to the overall mass of red blood cells. In healthy adults, red blood cells are produced in the bone marrow at a rate of ~2.4 million cells per second, and have a life span of ~120 days. Their production is completely dependent on the 30.4 kDa glycoprotein hormone erythro poietin, circulating levels of which consequently regulate total red blood cell mass. Erythropoietin is largely produced by the kidneys; thus chronic kid ney disease (CKD) can lead to anaemia as a result of impaired erythropoietin production.
Current treatment of renal anaemia
Until the 1980s, renal anaemia was usually managed with regular blood transfusions. Problems with this approach, however, included sensitization to red cell antigens (which limited the range of compatible blood donors), sensitization to HLA antigens (which restricted subsequent transplantation), exposure to bloodborne infections, and iron overload 4 . As a con sequence of these hazards, together with the logisti cal challenges of transfusion, low levels of circulating haemoglobin in patients with renal anaemia were commonly considered to be acceptable.
Research published in the late 1980s showed that recombinant human erythropoietin (rhEPO), which was generated from stably transfected Chinese hamster ovary cells, provided a safe and highly effective therapy for renal anaemia 5 . This therapy transformed the lives of patients with renal disease, and the worldwide mar ket for rhEPO and its derivatives (collectively referred to as conventional erythropoiesis stimulating agents [ESAs] ) rapidly grew over the following two decades to over US$10 billion per annum.
Renal anaemia is now an established indication for pharmaceutical treatment, and several companies mar ket conventional ESAs. The initial products had amino acid compositions that were identical to human eryth ropoietin. The WHO International Nonproprietary Names of these preparations are epoietin, followed by a Greek letter that differentiates them with respect to the cell line in which they are produced, differences in glycosylation, and other characteristics. Longeracting erythropoietin analogues, which enable administra tion at fortnightly or monthly intervals rather than three times per week, have since been developed by substituting amino acids to provide additional gly cosylation sites (darbepoetin alfa) or by pegylation (methoxy polyethylene glycolepoetin beta). The effi cacy and safety of available preparations seem to be similar 6, 7 . Peginesatide is a pegylated peptide activa tor of the erythropoietin receptor that has a sequence that is unrelated to erythropoietin but an efficacy equal to that of darbepoetin alfa 8, 9 . Peginesatide was also effective in patients with severe anaemia caused by anti erythropoietin antibodies after treatment with rhEPO or its derivatives 10 . However, pegine satide was withdrawn by the manufacturers because of hyper sensitivity reactions that were observed after licensing 11, 12 . Data from patients with nondialysis dependent CKD also suggested that peginesa tide is associated with cardiovascular problems to a greater extent than are conventional ESAs 8 . Experience of treating renal anaemia with con ventional ESAs has shown that functional iron defi ciency is a common consequence of anaemia, related to increased iron consumption and, at least in part, to elevated levels of hepcidin 13 . Conventional ESAs are therefore often effective at lower doses if administered with intravenous iron.
Conventional ESAs have proven to be largely safe for the treatment of renal anaemia. Adverse effects that were observed when these therapeutics were first intro duced included increased blood pressure, seizures and a high rate of thrombotic events that affected shunts and arteriovenous fistulae 5 . Approaches to dosing that aim to slowly increase the haematocrit seem to min imize these problems. Nevertheless, two important safety issues remain.
The first is that patients can develop antibodies against conventional ESAs when they are adminis tered sub cutaneously, although usually not when they are administered intravenously 14 . Antibodies against conventional ESAs can also neutralize native eryth ropoietin, leading to the development of pure red cell aplasia. The reported incidence of immune reactions is 14.0-35.8 cases per 100,000 patient years of treatment 15 . The second safety issue is that the use of conven tional ESAs with a target haemoglobin concentration within the normal range has been associated with a higher rate of cardiovascular events and possibly excess mortality than when used with a lower target haemoglobin level 16, 17 . The reason for these harm ful effects is unclear; possibilities include offtarget effects of high concentrations of conventional ESAs or a real benefit of lower haemo globin concentrations 18 . Regardless, the finding has led to FDA boxed warn ings for conventional ESAs 19 and to the reformulation of treatment guidelines 20 . As a result of these safety issues and other limita tions of current anaemia therapy, considerable interest exists in identifying smallmolecule alternatives to con ventional ESAs. These alternatives could be advanta geous for several reasons. For example, small molecules are simpler and cheaper to produce than recombinant poly peptides and are inherently more stable, making their distribution simpler, safer and less expensive. Small mol ecules can be administered orally rather than by injection, and would eliminate the risk of patients developing antibodies that crossreact with erythropoi etin. Parallel effects on iron metabolism might enhance the ability to correct anaemia. Finally, a different strat egy for increasing the haemo globin concentration might be associated with a better cardiovascular profile than that of conventional ESAs.
Key points
• Erythropoietin production is controlled by hypoxia inducible factor (HIF); the prolyl hydroxylase domain-containing (PHD) enzymes regulate HIF and act as molecular oxygen sensors • Small-molecule inhibitors of the PHD enzymes increase erythropoietin production and are in clinical development for the treatment of renal anaemia • Advantages of PHD enzyme inhibitors over conventional erythropoiesis-stimulating agents (ESAs) include oral administration, lower production costs, product stability and low immunogenicity • PHD enzyme inhibitors have effects besides increasing production of erythropoietin.
Some of these effects could be beneficial, including improvements in uptake and utilization of iron • The balance of risks and benefits in treating renal anaemia with PHD enzyme inhibitors is currently being addressed in randomized controlled trials • PHD inhibitors might be useful for therapeutic indications other than the management of renal anaemia
Physiological erythropoietin production

Molecular pathway
The molecular pathway that regulates erythropoietin production in an oxygendependent fashion centres on HIF, which increases expression of specific target genes by binding to hypoxia response elements across the genome 1 (FIG. 1) 30 . PHD enzymes require oxygen as a substrate and thereby act as the oxygen sensor that regulates HIF. In vitro measure ments have shown that the hydroxylation rate by PHD enzymes is sensitive to oxygen throughout the range of oxygen concentrations that occur physiologically 31 . Additional HIF regulation occurs through oxygen dependent hydroxylation of an asparagine residue near the Cterminus of the α subunit. This hydroxylation is mediated by the 2OGdependent oxygenase factor inhibiting HIF1 (FIH1) and blocks recruitment of the transcriptional coactivator CREB-EP300 (REF. 32 ).
Importantly, expression of HIF is not restricted to cells that produce erythropoietin and it regulates the expression of several hundred genes in all mammalian cell types examined to date 33 . Its role is, therefore, not spe cific to erythropoietin production, but rather it coordi nates a wide range of adaptive responses to changes in oxygenation. Besides erythropoietin, other genes that are regulated by HIF and contribute to adaptation in response to altered oxygenation include those that encode glucose transporters, glycolytic enzymes and angiogenic growth factors 1, 33 (FIG. 2) . HIF also affects the expression of genes with less obvious roles in such adaptation, but which are involved in diverse pathways, including cell cycle control, cell survival decisions and immune responses.
In addition, PHD enzymes and FIH1 probably have roles in the regulation of other cellular pathways. For example, PHD enzymes have been reported to modu late multiple aspects of the NFκB pathway 34 , and FIH hydroxylates many proteins that have ankyrin repeats, including components of the Notch signalling path way, although the function of this hydroxylation is currently unclear 35, 36 .
Erythropoietin-producing cells
Fibroblasts of the renal cortex and outer medulla are the principal cells that produce erythropoietin in response to hypoxia or anaemia 37, 38 . The origin and characteristics of these cells are not fully understood, but they are thought to derive from the neural crest; GATA transcription fac tors are thought to have an important role in silencing the EPO gene in other renal cells 39 .
Role of HIF-2α and PHD2
In humans and rodents, renal fibroblasts activate HIF2α in response to hypoxia, without detectable activation of HIF1α 40, 41 . This observation suggests that HIF2α, but not HIF1α, is pivotal in normal erythropoietin pro duction, a hypothesis that is supported by other lines of evidence. Knockout experiments in mice indicated that HIF2α is required for normal erythropoiesis 42 . In humans, mutations that activate HIF2α can result in erythrocytosis 43, 44 , and genetic variants of HIF2α are associated with differences in haematocrit between people who live at the same level of high altitude in the Himalayas 45, 46 . Nature Reviews | Nephrology Further evidence suggests that PHD2 is the enzyme that predominantly regulates HIF2α stability upstream of erythropoi etin production: in cultured cells, PHD2 seems to be the dominant HIF prolyl hydroxylase under normal circumstances, and deletion or knockdown of PHD2 is sufficient to result in HIF activation 47, 48 . In humans, mutation of one PHD2 allele is sufficient to increase haematocrit, suggesting that a decrease in PHD2 activity is sufficient to increase EPO produc tion 49 . In line with this observation, the absence of PHD1, PHD3 or FIH in mice is not sufficient to increase the haematocrit 50, 51 .
PHD enzymes as therapeutic targets
Inhibitors of 2OGdependent oxygenases were first devel oped as potential antifibrotic agents due to their capacity to inhibit collagen hydroxylases and thereby collagen crosslinking 52, 53 (Supplementary Table 1 ). The discovery that enzymatic prolyl hydroxylation controls HIF degra dation rapidly led to the discovery that 2OG analogues activate HIF by inhibiting PHD enzymes 54 . This inhibition was initially demonstrated with dimethyloxalylglycine, a cellpermeable compound that is hydrolysed intracellu larly to form Noxalylglycine, which is a competitive 2OG oxygenase inhibitor that reduces HIF hydroxylation 54 . A substantial number of small molecule PHD enzyme inhibitors have subsequently been identified 2, 3, [55] [56] [57] . The diverse and important functions of 2OG dependent oxygenases suggest that ideal small molecule inhibitors of PHD enzymes for clinical use should be highly selective. However, the selectivity of current smallmolecule inhibitors among the 2OG dependent oxygenases remains largely unknown, and even knowl edge of their selectivity among PHD enzymes is limited. This lack of knowledge exists because assays are not yet available for a number of 2OGdependent oxygen ase enzymes, and the extent to which existing assays reflect in vivo activity is uncertain. Nevertheless, small molecule inhibitors with a high selectivity for PHD proteins over FIH, and smallmolecule inhibitors with high selectivity for specific PHD proteins have already been identified 2 .
Targeting PHD enzymes in renal anaemia
The ideal small molecule for the treatment of renal anaemia would efficiently increase circulating levels of endogenously produced erythropoietin in a way that would achieve a controllable, stable haemoglobin level Figure 2 | On-target and off-target effects of PHD enzyme inhibitors. The primary strategy for the treatment of renal anaemia is to target prolyl hydroxylase domain-containing (PHD)2, which will increase hypoxia inducible factor (HIF)-2α activity and increase erythropoietin production. Increasing the activity of HIF-1α and HIF-2α will also have other effects. Inhibiting PHD enzymes might also influence the activity of non-HIF targets with effects that are currently unknown. Inhibition of other 2-oxoglutarate dependent enzymes that are structurally related to the PHD enzymes could result in a range of off-target effects. ALKB, alpha-ketoglutarate-dependent dioxygenase; FIH, factor inhibiting HIF; JMJD, Jumonji domain-containing protein; KDM, lysine (K)-specific demethylase; P4HA, prolyl-4-hydroxylase; PLOD, procollagen-lysine 2-oxoglutarate 5-dioxygenase.
in patients with renal disease, without undesirable con sequences. However, several aspects of the HIF pathway and erythropoietin regulation in renal disease are insuf ficiently understood to precisely define the properties of compounds that would fulfil these goals.
Erythropoietin production in renal disease
Although inappropriately low erythropoietin production is undoubtedly the main cause of renal anaemia, little is known as to why erythropoietin production by renal fibroblasts is so severely impaired in renal disease 58, 59 , and why extrarenal tissues, in particular the liver, do not compensate for impaired renal production. Blunting of the erythropoietin response by uraemic toxins might contribute to the pathogenesis of renal anaemia 60 , and evidence suggests that an oral toxin adsorbent can improve renal anaemia in patients who are on dialysis 61 .
Residual erythropoietin production in CKD. Despite the impairment in erythropoietin production, patients with CKD do not completely lose the ability to produce the hormone and adjust its production according to oxygen availability. Even in patients who are on dialysis, plasma levels of erythropoietin can increase in response to acute episodes of hypoxia or acute decreases in haemoglobin, despite an inadequate response to a chronic reduction in haemoglobin concentration [62] [63] [64] . Moreover, at increas ingly high altitudes, patients who are on haemodialysis require lower doses of conventional ESAs, yet maintain higher levels of haemoglobin, suggesting that their resid ual erythropoietin production responds to a reduction in the partial pressure of oxygen in the atmosphere 65 . Residual erythropoietin produced by chronically dis eased kidneys can be dysregulated: for example, persis tent production of erythropoietin by remnant kidneys contributes to erythrocytosis that occasionally occurs after successful renal transplantation 66, 67 .
Production by cystic kidneys. Erythropoietin produc tion is often preserved when cysts are present in dis eased kidneys. This preservation is a typical feature of autosomal dominant polycystic kidney disease 68 , and development of cysts in the kidneys after years of renal replacement therapy is sometimes associated with a return of erythropoietin production and an increase in haemoglobin levels 69 . Compression of the microvascu lature in the interstitial space around the cysts results in hypoxia 70 ; consequent HIF2α activation in inter stitial cells probably stimulates erythropoietin synth esis and mitigates renal anaemia. Additionally, hypoxia occurs in the cyst epithelium, where HIF1α promotes cyst expansion, thereby presumably further increasing regional hypoxia 71 .
Production in the liver and other organs. The liver is a second main source of erythropoietin, where the hor mone is produced by stellate cells and hepatocytes 72, 73 . The liver is the predominant site of erythropoietin production during fetal and early postnatal life, and might also contribute to erythropoietin production in adulthood, although the extent of this contribution is unclear. In rats exposed to severe hypoxia, approxi mately onethird of total erythropoietin is produced in the liver 74 . Renal impairment decreases expression of the EPO gene in the rat liver, suggesting a mechanism that prevents compensation for reduced renal erythropoietin production by the liver, despite its capacity to produce the hormone 74 . Before the availability of rhEPO, some patients with renal disease achieved a normal haemato crit without blood transfusion during recovery from hepatitis 75 , and studies in rodents have shown that active liver regeneration is associated with high erythropoietin production 76 . Together, these data suggest that both the liver and kidney could be targeted by therapy that aims to increase erythropoietin production in renal disease.
Therapeutic strategies that target erythropoietin pro duction in the liver are particularly attractive for patients with kidney disease because the ability to increase pro duction in their diseased kidneys is likely to depend on the extent of disease, renal pathology and the remaining renal mass. Despite many similarities, the mechanisms that regulate erythropoietin production in the liver are not identical to those in the kidneys. The importance of regulatory elements of the EPO gene differs in hepato cytes and the kidney 77 . As in the kidney, HIF2α seems to mediate hypoxic stimulation of erythropoietin pro duction in hepatocytes 78 . However, a genetic study in mice showed that efficient production of erythropoi etin by hepatocytes cannot be achieved by inactivating PHD2 alone 79 . Inactivation of PHD3 alone, by contrast, resulted in selective activation of HIF2α in hepatocytes, and combined inactivation of any combination of two PHD enzymes, or of all three PHD enzymes, stimulated extensive hepatic production of erythropoietin 78, 79 . The ability to produce erythropoietin is not confined to the liver and kidneys, and has been demonstrated in other cell populations, including astrocytes 80 and osteo cytes 81 , in mice. Extrarenal and extrahepatic erythropoi etin production can induce polycythaemia; for example, cerebellar haemangioblastomas have been associated with polycythaemia in humans 82 . However, a relative deficiency of circulating erythropoietin is a hallmark of advanced kidney disease, and thus erythropoietin pro duction at extrarenal sites clearly cannot compensate for the impairment of renal erythropoietin production.
Therefore, neither the most effective approach to inhibiting PHD proteins nor the organs that would ideally be targeted in patients with renal disease are cur rently clear, but the available evidence seems to favour targeting of PHD2 and PHD3 in the liver.
Pleiotropic effects of HIF activation
HIF directly influences the expression of hundreds of genes, and consequently HIF has roles in pathways other than the regulation of erythro poietin. Furthermore, evi dence suggests that HIF activation has indirect effects via epigenetic mechanisms 83, 84 . HIF activation could modulate almost any developmental, physiological or pathological process, and so inhibition of PHD proteins will have a range of effects beyond increasing erythro poietin production. These effects could be beneficial, harmful or neutral.
Potential beneficial effects. Beneficial effects of HIF acti vators, when compared with conventional ESAs, can be considered in two categories. The first is the more effec tive treatment of renal anaemia than can be achieved with conventional ESAs. For example, treatment with conventional ESAs is often limited by functional iron deficiency, so considerable interest exists in new pharma cological strategies to address functional iron deficiency, especially in anaemia that is associated with chronic inflammation 85, 86 . Several genes that are involved in iron homeostasis are regulated by HIF 87 , and experiments in mice suggest that HIF activation directly suppresses hepcidin production by the liver 88 , although subsequent evidence suggests that this suppression of hepcidin is an indirect effect 89, 90 . Early clinical data indicated that PHD enzyme inhibitors reduce hepcidin levels in patients with renal disease [91] [92] [93] . However, conventional ESAs also sup press hepcidin 94, 95 , probably by increasing production of erythroferrone in erythroblasts 96 . An important ques tion is whether the need for parenteral iron supplemen tation will be reduced by treatment with PHD enzyme inhibitors compared with conventional ESAs.
The second category of potential benefits of PHD inhibitors are reductions in the high rate of cardio vascular events associated with renal disease. Such bene fits could result from effects on cardiovascular risk factors by reducing blood pressure 57 or improving glucose toler ance and lipid profiles 97 . Preclinical evidence also sug gests an ability of PHD inhibitors to protect organs from ischaemic injury 98 . Whether such effects are sustained and translate into reductions in mortality and morbid ity can only be determined by largescale, appropriately controlled clinical trials that are currently underway but have not yet been completed (see Clinical trials below).
Efficient treatment of anaemia and an improved cardio vascular prognosis could be linked. Provided that high concentrations of erythropoietin may be harmful and if PHD enzyme inhibitors can be used to achieve similar haemoglobin concentrations with much lower concentrations of circulating erythropoietin, morbidity might be reduced. Carefully performed, large clinical trials will be needed to test this hypothesis.
Potential harmful effects.
Human diseases that involve genetic alterations in the HIF pathway provide the clear est insight into the potential harm of HIF activation. For example, von Hippel Lindau disease results from a germline mutation in one copy of VHL, which encodes the Von Hippel Lindau disease tumour suppressor (VHL); affected individuals are at high risk of clear cell renal cell carcinoma (CCRCC), pheochromocytoma and haem angioblastomas of the retina, cerebellum and spinal cord 99 . The tumours arise from somatic muta tions in the remaining functional copy of VHL, and are associated with impaired degradation of HIF. Particular attention has been given to the role of this mechanism in spontan eous CCRCC, which is the most common form of kidney cancer. The majority of CCRCCs in patients without any family history of VHL disease have biallelic somatic inacti vation of the VHL gene 100 . Although VHL probably has other important roles 99 , multiple lines of evidence indicate that HIF activation (particularly HIF2α) is pivotal in the development of CCRCC [101] [102] [103] . This cancer promoting role of HIF is a concern with therapeutic strategies that are based on activating the HIF pathway. However, in mice and patients with von Hippel Lindau disease, VHL inactivation alone, and consequent HIF activation in renal epithelial cells, does not seem to cause a large increase in cell proliferation; several addi tional genetic events are necessary for CCRCC to develop following VHL inactivation 102, 104, 105 . The role of HIF activation in pheochromocytoma is less clear than in CCRCC. Mutations in VHL that are associated with familial pheochromocytoma do not seem to influence the ability of VHL to regulate HIF, and mutations in VHL that completely disable HIF regulation are actually associated with a low risk of pheo chromo cytoma 106 . These observations suggest that pheo chromocytoma might result from a HIFindependent consequence of VHL inactivation. However, germline mutations in HIF2A, PHD2 and PHD1 have now been implicated in pheochromocytoma, providing strong evi dence that the HIF-PHD-VHL pathway is involved 107, 108 . One possible unifying explanation is that incomplete acti vation of the HIF pathway during development promotes pheochromocytoma formation but complete loss of VHL function does not.
These genetic insights indicate that activation of the HIF pathway could promote development of CCRCC or pheochromocytoma, but pharmacological HIF acti vation could also promote progression of other can cers by increasing angiogenic signalling 109 , promoting metabolic reprogramming 110 , and driving epithelialto mesenchymal transition [111] [112] [113] and metastasis 114 . Although this possibility is a concern in the development of HIF activators, evidence from studies of three genetic condi tions that cause HIFdependent congenital erythrocyto sis is reassuring. No increased risk of CCRCC or other malignant neoplasms has been apparent in patients with biallelic hypomorphic mutations in VHL that decrease the ability of VHL to ubuiquitinate hydroxylated HIF (Chuvash polycythaemia) 115 , mutations in HIF2A that increase activity of HIF2α and partially protect it from PHD enzymemediated hydroxylation 43, 44, 116 , or mutations in PHD2 that decrease PHD2 activity 49 . The total number of patients with these mutations who have been studied, however, is limited.
Studies of conditions that involve genetic HIF activa tion have identified two other potential problems with HIF activation as a therapeutic strategy. The first is the possi bility of severe pulmonary hypertension, which develops in some individuals with HIF2A mutations 44, 117 . Persistent HIF activation is the likely cause of this condition, as humans with Chuvash polycythaemia have higher base line pulmonary artery pressure and a stronger constrictive response to hypoxia than do healthy controls 118 . Mice with the mutation that causes Chuvash polycythaemia also develop HIFmediated pulmonary hypertension 119 . The second potential problem is that Chuvash polycythaemia is associated with a reduced life expectancy. A study that compared 76 patients with healthy controls found that the estimated survival to age 65 years was 29% for patients with Chuvash polycythaemia and 64% for controls 120 . This high mortality has not yet been fully explained, but is associated with a marked increase in thromboembolic events 120 . The rate of thromboembolism was 5.6fold lower in patients with Chuvash polycythaemia who received therapeutic phleb tomy than in patients who were untreated, although this difference was not statistically significant (95% CI 0.70-47.6, P = 0.12). Nevertheless, the association warrants prospective study 120 
.
Animal and in vitro studies have indicated that HIF activation could have other harmful effects, including angiotensininduced vascular remodelling 121 and adverse effects on atherosclerotic plaque homeostasis 122 . Whether longterm PHD enzyme inhibition could alter the pro gression of kidney disease is uncertain. HIF activation over long periods promotes renal fibrosis, which could accelerate CKD 41, 113 . However, HIF activation in animal models has indicated that inhibiting PHD enzymes could protect against CKD progression [123] [124] [125] [126] [127] . In light of these disparate preclinical findings, the effect of PHD enzyme inhibitors on renal function in humans with CKD is difficult to predict and is an important question that should be addressed in randomized trials (see Clinical trials below).
Potential off-target effects. In addition to the 'ontarget' risks associated with inhibiting PHD enzymes, any small molecule inhibitor of PHD enzymes is likely to have 'offtarget' effects associated with inhibition of other 2OGdependent enzymes (FIG. 2; Supplementary Table 1) .
Clinical development of PHD enzyme inhibitors
Despite the potential risks, PHD enzyme inhibitors are an attractive treatment for renal anaemia for several reasons. The target is well validated, the number of patients with renal anaemia is large, and current treatment is imperfect. The efficacy of PHD enzyme inhibitors is easily meas ured by monitoring levels of circulating erythropoietin and haemoglobin. Furthermore, the main target organ is likely to be the liver, so oral medication should be delivered efficiently and predictably to the desired site of action, and inhibition of PHD proteins needs to be only partial and intermittent to increase erythropoi etin production and the haematocrit. Judicious selection of a low dose, infrequent administration and moni toring of haemo globin levels could, therefore, increase the safety margin and facilitate individualized therapy. Reassuringly, the results of preclinical programmes indi cate that smallmolecule PHD enzyme inhibitors effec tively increase erythro poietin levels and the haematocrit in healthy animals and in animals with renal impairment, without serious safety concerns 56, 57 .
Requirements for trial design
The design of trials of PHD enzyme inhibitors should take into consideration multiple factors. The com plexity of the HIF system and the widespread role of 2OGdependent oxygenases mean that the biological effects of different PHD enzyme inhibitors might vary according to their pharmacokinetic and pharmaco dynamic properties and the dosing regimens used. These dosing regimens will need to be optimized, as ideal thresholds for intervention, target levels of haemoglobin and the most effective combinations with iron therapy might differ from those of conventional ESAs. Phase III trials in patients on dialysis need to evaluate the cardio vascular safety of PHD enzyme inhibitors in direct com parison with conventional ESAs as the current standard of care. For patients who are not on dialysis, trials should be placebocontrolled. In both cases, trials must include several thousand patients to ensure that they accurately determine the effects on mortality and rates of major cardio vascular events. In trials involving conventional ESAs, current recommendations for target haemoglo bin levels should probably be adhered to, although the risk-benefit relationship for different target levels might differ when PHD enzyme inhibitors are used rather than conventional ESAs. Recruiting enough patients who meet the entry criteria will be a challenge, owing to the complex landscape of anaemia treatment that includes a considerable number of established, conventional ESAs.
Understanding the benefits and risks of PHD enzyme inhibitors in specific populations and clinical settings will pose additional questions; for example, specific patient groups might be at higher risk of some adverse events (for example, malignancy or pulmonary hypertension), and these groups are unlikely to be represented suffi ciently in initial trials. Carefully planned smaller stud ies could also be valuable in determining the effects of PHD enzyme inhibitors on specific aspects of vascular biology, organ function and metabolism. Some effects of HIF activation might only become apparent after a dec ade or more of administration, so longerterm assessment of outcomes would also be desirable. Overall, extensive trial programmes will be necessary to fully understand the benefits and risks to patients in different settings.
Current clinical trials
At least six PHD enzyme inhibitors have been tested in humans to date (FIG. 3; TABLE 1 ). In a small proofof concept study, a single dose of FG2216 (20 mg/kg) Nature Reviews | Nephrology significantly increased erythropoietin levels in six healthy volunteers and 12 patients on haemo dialysis, six of whom still had their native kidneys, and six of whom had no kidneys 128 . In patients on haemodialysis and who still had kidneys, the increase was variable but much greater on average than the response in patients with no kidneys, suggesting that FG2216 induced erythro poietin production in the nonfunctioning kidneys. The increase in serum erythro poietin levels in patients with out kidneys confirms that erythropoietin production occurs at extrarenal sites, presumably in the liver. The programme to test FG2216 was suspended because one participant of a later trial died from fulminant hepatitis, although the death was subsequently deemed not to be caused by the drug 3 . Several trials of other smallmolecule PHD enzyme inhibitors have been conducted or are underway (TABLE 1) . The most advanced current clinical pro gramme concerns roxadustat (FG4592), which has been shown to correct renal anaemia in humans and is currently in Phase III trials 3 . A phase IIa study showed a dose dependent increase in haemoglobin levels in patients with non dialysisdependent CKD who were treated with roxadustat for 4 weeks 129 . A phase IIb study showed that in patients incident to haemodialysis or peritoneal dialysis who received titrated doses of roxa dustat over 12 weeks, haemoglobin levels increased by 31 ± 2 g/l 130 . In the latter study, no difference was seen in the haemoglobin response in patients on haemodialysis regardless of whether they received oral or intravenous iron supplementation 130 . Preclinical studies of molidustat (BAY85-3934) have shown that the drug corrects renal anaemia in rats and that, unlike treatment with epoietin, it normalizes hypertensive blood pressure in a rat model of CKD 57 . The results of a Phase I trial have been disclosed in an abstract: dosedependent increases in haematocrit were observed in healthy male subjects 131 . Results of two 4week phase IIa studies of daprodustat (GSK1278863) showed a dose dependent increase in haemoglobin lev els in patients with nondialysisdependent CKD, and a dosedependent ability to maintain stable haemoglobin levels in patients on haemodialysis who had previously been treated with conventional ESAs 132 . A 2week study of daprodustat in patients with claudication found that a low dose of the drug, which did not increase haemo globin levels, caused significant decreases in the levels of total cholesterol, LDL and HDL but did not improve ischaemic symptoms 97 . This finding demonstrates that this class of drug is likely to have clinically meaningful effects in addition to increasing erythropoietin.
The results of phase III trials should be available within 2-3 years (TABLE 1) . These studies will involve exposure of participants to smallmolecule PHD enzyme inhibitors for up to 2 years and will provide important information about the rate of adverse effects. Good tolerance and efficacy of a PHD enzyme inhib itor will probably lead to licensing approval of the treatment for patients with renal anaemia. If trials that include thousands of patients do not reveal any safety issues, the advantages of an orally administered small molecule will make this treatment more attractive to patients, prescribers and payers than injections of a biological agent.
Other indications for PHD inhibitors
Current understanding of HIF biology suggests sev eral other settings in which PHD enzyme inhibitors might be an effective therapeutic approach. Although the current focus in the development of PHD enzyme inhibitors is the management of anaemia, studies that test PHD enzyme inhibitors for other indications could be worthwhile.
In haematological conditions, PHD enzyme inhibi tors could be used to increase the haematocrit in anae mia of chronic disease and to increase fetal haemoglobin levels in, for example, sickle cell disease 56 . Activation of HIF might be particularly beneficial in ischaemic or ischaemia-reperfusion settings, as HIF acts upstream of diverse gene products that should be protective in these contexts by, for example, promo ting vasodilatation and angiogenesis, increasing glucose uptake, modulating mitochondrial metabolism and decreasing free radical production 1 . Evidence exists to support the use of PHD enzyme inhibitors in this con text: preconditioning of the brain, heart or kidney with a short period of ischaemia protects against a subsequent longer ischaemic exposure 133 , and this protective effect is mediated in part by HIF 134, 135 . Preclinical experiments suggest that HIF activation might be beneficial in stroke 136 , myocardial ischae mia 137, 138 , limb ischaemia 139, 140 , acute kidney injury 98, [141] [142] [143] and kidney transplantation 144 . In many of these experi ments, PHD enzyme inhibitors were administered before ischaemic injury, so their relevance to most clini cal settings, in which acute ischaemia is not predictable, is limited. However, ischaemic injury can be anticipated in some cases; for example, a PHD enzyme inhibitor could be administered before major cardiac surgery to protect against stroke and acute kidney injury. Another possible application is in renal transplantation, whereby a kidney from a braindead donor could be treated with a PHD inhibitor to prevent ischaemia-reperfusion injury and delayed graft function, as has been demonstrated in an animal model 144 . Whether these preclinical obser vations will translate into useful therapies in humans remains to be seen. Similar preclinical observations with conventional ESAs have been followed by negative clinical studies 145 , but in our view the broad biological effects of activating the HIF system make this approach more promising.
PHD enzyme inhibitors might also be of benefit in wound healing. In this context, stimulation of angio genesis and cell migration might accelerate healing, and topical application would minimize the likelihood of systemic adverse effects 146 .
Conclusions
In our view, the PHD enzymes are an exciting new ther apeutic target. However, the underlying biology of the HIF pathway suggests that the targeting of PHD pro teins will have pleiotropic effects. Moreover, the inhibi tors that are currently being tested will almost certainly inhibit other 2OGdependent oxygenases to some extent. However, the intended outcome of increased erythropoietin production can be achieved with partial and intermittent inhibition, which might minimize these potential liabilities. In the best case scenario, treatment of renal anaemia with PHD enzyme inhibitors will be safe and effective, and could reduce the substantial risk of mortality that is associated with serious renal disease. With the results of latephase clinical trials that are cur rently underway, we will hopefully soon know whether this bestcase scenario will become a reality.
